Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial

Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial

Introduction Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may decrease progression of chronic kidney disease. H...

Full description

Saved in:
Bibliographic Details
Main Authors: Rajiv Agarwal, Ian Craig, Domenic J Reda, Grant D Huang, Kimberly Carlson, David J Leehey, Christina Clise, Todd A Conner, James S Kaufman, Robert J Anderson, Douglas Lammie, Jeffrey Huminik, Linda Polzin, Conor McBurney, Nicholas V Emanuele
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/8/e053019.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/11/8/e053019.full

Similar Items